What FDA said about peptides in the July 2026 committee documents

Key points

• FDA proposed that none of the 7 peptides be added to the 503A list. The committee voted for 6 [2][9][10].
• Votes: BPC-157, KPV and TB-500 8 to 6; MOTS-c 7 to 5; epitalon 7 to 5; Semax 8 to 5; emideltide (DSIP) rejected 6 to 7 [9][10].
• For KPV and TB-500, FDA found no documented human use at all [3][4].
• As of October 2026 we found no published rule adding these peptides to the list. The recommendation is non-binding [1][2].

US status (October 2026): BPC-157, TB-500, MOTS-c, epitalon and Semax are not FDA-approved and have no lawful compounding pathway; FDA has not acted on the vote. See the peptide status tracker.

The committee voted against its own agency’s scientists

On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides for the list of substances 503A compounding pharmacies may use: BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon and emideltide (DSIP) [1]. FDA’s introductory document was clear: it proposed that no form of any of the seven “NOT be included” [2].

A detail few reports picked up: every nominator had withdrawn its nomination before the meeting. FDA wrote that it nonetheless “is electing to proceed with the presentation” [2]. The committee voted in favor of six [9][10].

• 0 of 7: peptides recommended by FDA scientists [2]
• 6 of 7: peptides backed by the advisory committee [9][10]
• 0: rules published after the vote, as of October 2026 [1]

The votes

• BPC-157, KPV and TB-500: 8 for, 6 against, 1 abstention [9].
• MOTS-c: 7 to 5, 2 abstentions [9].
• Epitalon: 7 to 5, 1 abstention. Semax: 8 to 5 [10].
• Emideltide (DSIP): 6 for, 7 against, 1 abstention. The only one rejected [10].

Healio reports the epitalon vote as 7 to 4 to 1, against RAPS’s 7 to 5 to 1 [16][10].

FDA’s core problem is identity

The technical argument running through every document goes beyond the lack of trials. It is characterization. FDA described inconsistent naming, no impurity, aggregate or endotoxin data on certificates, and an immunogenicity risk “potentially amplified by aggregation” for injectable peptides [2][3]. FDA’s Russell Wesdyk put it this way: “We’ve never faced a problem of, ‘What is it?’” [9]. If you are vetting a source, that is the same question a certificate of analysis and supplier diligence have to answer.

Peptide by peptide, in FDA’s words

• TB-500: “FDA did not find any information in the medical literature where TB-500 was administered to patients”. In a fibroblast wound-healing assay at 50 µg/mL it “did not induce wound healing”. FDA also identified no acute or repeat-dose toxicity studies [3].
• KPV: “The nomination did not include, and FDA did not find any information on the use of these substances administered in humans” [4].
• Semax: in mice it “potentiated amphetamine-induced” dopamine release. Its antithrombotic effect “raises concern about the risk of bleeding”. There are no human pharmacokinetic studies. It is a registered drug in Russia as nasal drops [5].
• Epitalon: “has the potential to be carcinogenic”, because it activates telomerase and lengthens telomeres [6].
• Emideltide (DSIP): its action on the opioid system “could lead to development of addiction”. Insomnia trials were “inconclusive and at best preliminary” [7].
• MOTS-c: “the molecular targets through which MOTS-c acts remain unknown”, and FDA identified no clinical studies of the proposed uses and no human exposure data [8].

Several voting members run private clinics

The official roster shows that several voting members are founders or chief medical officers of private clinics or health companies [14]. For critics, that explains the gap between the vote and the technical recommendation. For supporters, it brings the experience of clinicians who see patients already using these products.

The supporters’ case, in their words

The clinicians who voted yes explained it this way: “I think it’s about patient access”; “Nobody put a finished product on a shelf. We took a decision that patients are already making”; “Our patients want peptides”; and FDA “has zero control over that channel” [16]. Supporters stressed the long history of use by licensed practitioners and argued that inclusion would allow more oversight than today’s gray market [17]. The full version of that argument is in Why doctors and patients defend peptides.

The vote changed nothing yet

The vote is non-binding. FDA considers the committee’s recommendations but is not legally bound by them, and it had not issued its final determination as of this writing [1]. Until it does, none of these peptides has a pathway, and a research use only label does not create one. What would have to happen next is covered in The FDA advisory vote on six peptides.

Meanwhile, the official 503A category list (updated May 2026) keeps ibutamoren (MK-677) and kisspeptin-10 in Category 2 [11]. FDA has also announced it will consult the committee before the end of February 2027 on GHK-Cu for non-injectable routes [11]. LL-37, dihexa and PEG-MGF are listed among substances whose nominations were withdrawn, with safety risks described by the agency [12].

Outside the US. FDA decisions have no legal effect in Latin America, but they shape the regional debate. Colombia’s INVIMA named several of these same peptides as unregistered, and Guatemala’s Health Ministry warned about unregistered injectable peptides [13][15].

What this means for you

The July vote gives you no new permission. Check each compound’s own status page before it goes on a menu, and recheck after FDA publishes its determination.

References

1. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Link
2. U.S. Food and Drug Administration. PCAC July 2026 briefing document: introduction. Link
3. U.S. Food and Drug Administration. PCAC July 2026 briefing document: TB-500. Link
4. U.S. Food and Drug Administration. PCAC July 2026 briefing document: KPV. Link
5. U.S. Food and Drug Administration. PCAC July 2026 briefing document: Semax. Link
6. U.S. Food and Drug Administration. PCAC July 2026 briefing document: Epitalon. Link
7. U.S. Food and Drug Administration. PCAC July 2026 briefing document: Emideltide. Link
8. U.S. Food and Drug Administration. PCAC July 2026 briefing document: MOTS-c. Link
9. Jacobus N. FDA panel votes to loosen restrictions for four peptides. Pharmaceutical Executive. 24 July 2026. Link
10. Eglovitch JS. FDA advisory committee backs two more peptides, rejects one for compounding list. RAPS. 24 July 2026. Link
11. U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A: categories (updated 14 May 2026). Link
12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Link
13. INVIMA (Colombia). Alerta Sanitaria No. 184-2026: DSIP, Selank, Semax, PT-141, ipamorelina, CJC-1295, BPC-157, GHK-Cu, TB-500 y retatrutida (productos fraudulentos). Bogotá, 24 de junio de 2026. Link
14. U.S. Food and Drug Administration. PCAC July 2026 roster. Link
15. Galicia S. El Ministerio de Salud de Guatemala advierte que los péptidos inyectables sin registro sanitario se venden de forma ilegal. Infobae. 6 de agosto de 2026. Link
16. Bascom E. FDA committee recommends looser restrictions for several peptides. Healio. 24 July 2026. Link
17. McDermott Will & Schulte. Bulk list bound? PCAC backs majority of peptides in two-day public meeting. 27 July 2026. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.